Product Description
Seanergy Dermatology is developing SNG-100 as a treatment for mild to moderate Atopic Dermatitis. (Sourced from: https://seanergypharma.com/)
Mechanisms of Action: IFNB Analogue
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seanergy Dermatology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SNG100 | P1 |
Unknown status |
Dermatitis, Atopic |
2022-01-01 |
22% |